| Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients R Lawson, CE Staatz, CJ Fraser, S Hennig Clinical Pharmacokinetics 60, 17-51, 2021 | 36 | 2021 |
| A population pharmacokinetic model of gentamicin in pediatric oncology patients to facilitate personalized dosing CC Llanos-Paez, CE Staatz, R Lawson, S Hennig Antimicrobial agents and chemotherapy 61 (8), 10.1128/aac. 00205-17, 2017 | 20 | 2017 |
| Gentamicin pharmacokinetics and monitoring in pediatric patients with febrile neutropenia S Bialkowski, CE Staatz, J Clark, R Lawson, S Hennig Therapeutic drug monitoring 38 (6), 693-698, 2016 | 16 | 2016 |
| Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell … R Lawson, L Paterson, CJ Fraser, S Hennig Cancer chemotherapy and pharmacology 88 (3), 379-391, 2021 | 15 | 2021 |
| Comparison of methods to estimate glomerular filtration rate in paediatric oncology patients CC Llanos‐Paez, C Staatz, R Lawson, S Hennig Journal of Paediatrics and Child Health 54 (2), 141-147, 2018 | 14 | 2018 |
| Antimicrobial stewardship in paediatric oncology: impact on optimising gentamicin use in febrile neutropenia S Hennig, CE Staatz, D Natanek, S Bialkowski, C Consuelo Llanos Paez, ... Pediatric Blood & Cancer 65 (2), e26810, 2018 | 12 | 2018 |
| Population pharmacokinetic model for once‐daily intravenous busulfan in pediatric subjects describing time‐associated clearance R Lawson, CE Staatz, CJ Fraser, S Ramachandran, L Teague, R Mitchell, ... CPT: Pharmacometrics & Systems Pharmacology 11 (8), 1002-1017, 2022 | 10 | 2022 |
| Differences in the pharmacokinetics of gentamicin between oncology and nononcology pediatric patients CC Llanos-Paez, CE Staatz, R Lawson, S Hennig Antimicrobial agents and chemotherapy 64 (2), 10.1128/aac. 01730-19, 2020 | 10 | 2020 |
| Internet video to support intravenous medication administration in the home: a cost minimisation study N Bradford, NR Armfield, J Young, M Ehmer, R Lawson, AC Smith Journal of telemedicine and telecare 19 (7), 367-371, 2013 | 8 | 2013 |
| A practical guide to palliative care in paediatrics N Bradford, A Herbert, L Pedersen, H Irving, J Collins, L Cooke, S Cohen, ... Brisbane: Queensland Health, 2014 | 5 | 2014 |
| Population pharmacokinetic model of gentamicin in paediatric oncology patients. CC Llanos-Paez, CE Staatz, R Lawson, S Hennig | 2 | 2016 |
| Intermittent micafungin dosing schedule in pediatric oncology patients‐safe for outpatient parenteral antimicrobial therapy? JA Fox, N Graham, R Lawson, S Stacey, JE Clark EJC Paediatric Oncology 4, 100189, 2024 | | 2024 |
| Comparison of methods to estimate busulfan exposure in paediatric bone marrow transplantation. N Siddique, CE Staatz, R Lawson | | 2024 |
| 825 Imaging in Suspected Gallstone Patients: Are We Optimising Resources? R Lawson British Journal of Surgery 110 (Supplement_7), znad258. 455, 2023 | | 2023 |
| Pharmacokinetics and pharmacodynamics of intravenous Busulfan in children: once daily dosing R Lawson | | 2023 |
| Examining different methods to assess busulfan exposure in paediatric stem cell transplant recipients. M Thompson, CE Staatz, CJ Fraser, R Mitchell, S Ramachandran, ... | | 2023 |
| Busulfan: A 2022 Perspective RA Lawson, CE Staatz, CJ Fraser, S Hennig | | 2022 |
| Exploration of time-dependent clearance associated with busulfan therapy in paediatrics RA Lawson, S Hennig, CJ Fraser, CE Staatz | | 2021 |
| Busulfan exhibits time-dependent clearance in paediatrics: exploration of five dose-adjustment scenarios R Lawson, CE Staatz, CJ Fraser, S Hennig | | 2021 |
| A population pharmacokinetic model of once daily intravenous busulfan in paediatrics characterising time-dependent clearance R Lawson, CE Staatz, CJ Fraser, S Hennig | | 2021 |
